"Pharmacokinetics and Pharmacodynamics" trang 1 - tải miễn phí từ tailieunhanh
Design of Controlled Release Drug Delivery Systems

Design of Controlled Release Drug Delivery Systems
1    85    0
Báo cáo hóa học:

Báo cáo hóa học: "A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability, and pharmacokinetics and pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock"
40    51    0
báo cáo hóa học:

báo cáo hóa học:" Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study"
14    42    0
Báo cáo y học:

Báo cáo y học: "Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study"
5    77    0
Ebook Essentials of pharmacology for anesthesia, pain medicine and critical care: Part 1

Ebook Essentials of pharmacology for anesthesia, pain medicine and critical care: Part 1
372    76    0
Ebook Illustrated pharmacology for nurses: Part 1

Ebook Illustrated pharmacology for nurses: Part 1
107    79    0
The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects
12    71    0
Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: Results from an open-label and from a randomised study

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: Results from an open-label and from a randomised study
11    43    0
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus
11    92    0
Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction

Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction
6    26    1
Antibiotic dosing in the ‘at risk’ critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients

Antibiotic dosing in the ‘at risk’ critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients
7    23    1
Lecture English for the pharmacy student - Vo Truong Toan University

Lecture English for the pharmacy student - Vo Truong Toan University
35    1    1
Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia: The PharmaCool multicenter study

Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia: The PharmaCool multicenter study
7    48    0
Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling

Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling
13    19    1
Pharmacokinetics and pharmacodynamics studies of a loading dose of cisatracurium in critically ill patients with respiratory failure

Pharmacokinetics and pharmacodynamics studies of a loading dose of cisatracurium in critically ill patients with respiratory failure
10    12    1
Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: A randomized, open-label, multiple dose, crossover study

Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: A randomized, open-label, multiple dose, crossover study
10    75    0